These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 30810283)
1. Cross-Interaction Chromatography-Based QSAR Model for Early-Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics. Kizhedath A; Karlberg M; Glassey J Biotechnol J; 2019 Aug; 14(8):e1800696. PubMed ID: 30810283 [TBL] [Abstract][Full Text] [Related]
2. QSAR Implementation for HIC Retention Time Prediction of mAbs Using Fab Structure: A Comparison between Structural Representations. Karlberg M; de Souza JV; Fan L; Kizhedath A; Bronowska AK; Glassey J Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126648 [TBL] [Abstract][Full Text] [Related]
3. An accelerated surface-mediated stress assay of antibody instability for developability studies. Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P MAbs; 2020; 12(1):1815995. PubMed ID: 32954930 [TBL] [Abstract][Full Text] [Related]
4. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. Kelly RL; Sun T; Jain T; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Vásquez M; Wittrup KD; Xu Y MAbs; 2015; 7(4):770-7. PubMed ID: 26047159 [TBL] [Abstract][Full Text] [Related]
5. A novel screening method to assess developability of antibody-like molecules. Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA MAbs; 2015; 7(4):752-8. PubMed ID: 25961854 [TBL] [Abstract][Full Text] [Related]
7. Development of QSAR models for Han X; Shih J; Lin Y; Chai Q; Cramer SM MAbs; 2022; 14(1):2062807. PubMed ID: 35442164 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in silico assessment of the developability of a designed monoclonal antibody library. Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N MAbs; 2019; 11(2):388-400. PubMed ID: 30523762 [TBL] [Abstract][Full Text] [Related]
9. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling. Park E; Izadi S MAbs; 2024; 16(1):2362788. PubMed ID: 38853585 [No Abstract] [Full Text] [Related]
10. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment. Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ MAbs; 2022; 14(1):2080628. PubMed ID: 35771588 [TBL] [Abstract][Full Text] [Related]
11. CISI: A Tool for Predicting Cross-interaction or Self-interaction of Monoclonal Antibodies Using Sequences. Dzisoo AM; He B; Karikari R; Agoalikum E; Huang J Interdiscip Sci; 2019 Dec; 11(4):691-697. PubMed ID: 31119495 [TBL] [Abstract][Full Text] [Related]
12. Exploring the QSAR's predictive truthfulness of the novel N-tuple discrete derivative indices on benchmark datasets. Martínez-Santiago O; Marrero-Ponce Y; Vivas-Reyes R; Rivera-Borroto OM; Hurtado E; Treto-Suarez MA; Ramos Y; Vergara-Murillo F; Orozco-Ugarriza ME; Martínez-López Y SAR QSAR Environ Res; 2017 May; 28(5):367-389. PubMed ID: 28590848 [TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Antibody Profiler for Computational Developability Assessment. Raybould MIJ; Deane CM Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133 [TBL] [Abstract][Full Text] [Related]
14. QSAR models for prediction of chromatographic behavior of homologous Fab variants. Robinson JR; Karkov HS; Woo JA; Krogh BO; Cramer SM Biotechnol Bioeng; 2017 Jun; 114(6):1231-1240. PubMed ID: 27943241 [TBL] [Abstract][Full Text] [Related]
15. A machine learning strategy for the identification of key Waight AB; Prihoda D; Shrestha R; Metcalf K; Bailly M; Ancona M; Widatalla T; Rollins Z; Cheng AC; Bitton DA; Fayadat-Dilman L MAbs; 2023; 15(1):2248671. PubMed ID: 37610144 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel HIV-1 Integrase Inhibitors Using QSAR-Based Virtual Screening of the NCI Open Database. Ko GM; Garg R; Bailey BA; Kumar S Curr Comput Aided Drug Des; 2016; 12(2):135-53. PubMed ID: 27076270 [TBL] [Abstract][Full Text] [Related]
17. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR MAbs; 2022; 14(1):2020082. PubMed ID: 35104168 [TBL] [Abstract][Full Text] [Related]
18. Five computational developability guidelines for therapeutic antibody profiling. Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520 [TBL] [Abstract][Full Text] [Related]
19. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L MAbs; 2020; 12(1):1743053. PubMed ID: 32249670 [TBL] [Abstract][Full Text] [Related]